Risk stratification strategies for cancer-associated thrombosis: an update
Risk stratification strategies for cancer-associated thrombosis: an update
复制标题
DOI：
10.1016/s0049-3848(14)50006-0
复制
发表时间：
2014-05-01
影响因子：
7.5
通讯作者：
McCrae, Keith R.
中科院分区：
文献类型：
--
作者：
Khorana, Alok A.;McCrae, Keith R.
不同癌症患者静脉血栓栓塞症(VTE)的发生率有很大差异。多种临床危险因素，包括肿瘤的原发部位和全身治疗，以及包括白细胞和血小板计数和组织因子在内的生物标志物，都与VTE的风险增加有关。然而，不能基于单一的风险因素或生物标志物可靠地预测风险。美国临床学会的新指南建议癌症患者在化疗开始时评估静脉血栓栓塞症风险，并在化疗后定期进行评估。本叙述性回顾提供了风险分层方法的最新信息，包括经过验证的风险评分。概述了风险评估的潜在应用，包括靶向血栓预防。(C)2014爱思唯尔有限公司。保留所有权利。
Rates of venous thromboembolism (VTE) vary substantially between cancer patients. Multiple clinical risk factors including primary site of cancer and systemic therapy, and biomarkers including leukocyte and platelet counts and tissue factor are associated with increased risk of VTE. However, risk cannot be reliably predicted based on single risk factors or biomarkers. New American Society of Clinical Guidelines recommend that patients with cancer be assessed for VTE risk at the time of chemotherapy initiation and periodically thereafter. This narrative review provides an update on risk stratification approaches including a validated Risk Score. Potential applications of risk assessment including targeted thromboprophylaxis are outlined. (C) 2014 Elsevier Ltd. All rights reserved.